GLP-1Research peptide

Survodutide

Survodutide is an investigational dual agonist peptide that activates both GLP-1 and glucagon receptors. It is under clinical investigation by Boehringer Ingelheim and Zealand Pharma for metabolic and hepatic research endpoints.

Also known as: BI 456906

Technical information

Molecular weight

4857.6 g/mol

Half-life

~6-7 days (subcutaneous)

Sequence

Modified 29-amino acid peptide (GLP-1/glucagon dual agonist)

Common research doses

0.6-6 mg weekly (research protocols)

Research areas

Metabolic researchMASH studiesWeight studiesDual agonism

For research purposes only. PepAssure provides vendor information as a verification service and does not endorse or recommend any specific use. Consult qualified research protocols and institutional review boards.